Record order book, but delivery growth trails guidance
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met manufacturing margin guidance (13.7%). Missed prior 10-12% consolidated revenue growth (9.4% delivered). Projects margin 5.7% vs 6% target is on track.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong order book (₹8,757 Cr) and capex momentum support medium-term upside, but Q2 delivered consolidated growth of 9.4% YoY trails the prior 10-12% guidance and upcoming 15-17% target. Subsidiary drag (Philippines -₹164 Cr, Saraswati weak) masks standalone strength. Margin expansion in core manufacturing (13.7% vs 12-13% guided) offset by near-term execution risk.
₹1850.4 Cr
Revenue · +9.4% YoY₹66.2 Cr
Reported PAT · +17.6% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue grew 17% YoY for the quarter
OVERSTATEDStandalone grew 17% but consolidated delivered 9.4% growth YoY
Manufacturing EBIT margin 13.7% beats 12-13% guidance
METQ2 manufacturing margin 13.7% vs guided 12-13% range
Order book at all-time high ₹8,757 Cr
METSep 30, 2026 order book confirmed ₹8,757 Cr closing position
Projects EBIT margin 5.7% vs 6% target
METDelivered 5.7%, tracking toward 6% by year-end
Earnings quality
What changed since the last call
Revenue growth guidance raised
UpgradePrior call: 10-12% FY27 standalone. This call: 15-17%. Delivered Q2: 9.4% consolidated. Upgrade driven by order book visibility (₹4,844 Cr H1 booking) vs prior uncertainty. Gap reflects subsidiary headwinds.
Manufacturing margin beat
UpgradeQ2 13.7% vs 12-13% guided. Projects margin 5.7% vs 6% on track. Indicates pricing power & cost control despite commodity inflation.
Capex trajectory firmed
NeutralMaintained ₹502 Cr capex for ₹1,200 Cr revenue potential by FY29. New facilities (Bhartoli, SEZ, Dabhei, Ratangarh, Hawa) on schedule. Management evaluating potential to increase from ₹500 Cr mentioned.
Subsidiary losses crystallized
DowngradePhilippines ethanol cumulative -₹164 Cr H1 loss (depreciation, interest, forex). Saraswati Sugar -₹60 Cr PBIT H1 vs prior strength. Consolidated growth 9.4% YoY vs standalone 17%, confirming ~750-800 bps drag.
The Q&A
Analyst Manish Goyal pressed aggressively on 15% guidance vs incremental H1 growth already achieved. Management held firm, citing second half smaller but defended full-year. On Philippines, management was evasive (blamed depreciation method change, seasonal feedstock). Direct questions on Saraswati supply, Hitachi JV margins drew guarded responses. Q&A showed confidence on order execution but limited transparency on subsidiary path to profitability.
Revenue growth guidance credibility — Manish Goyal, Thingwise Wealth Managers
PartialH1 was 3,000 Cr, H2 expected 3,200-3,300 Cr run rate. Small H2 growth but strong order pipeline justifies guidance. Base already higher, so % growth lower. Second half orders converting gradually.
Cavite Biofuel depreciation volatility — Manish Goyal, Thingwise Wealth Managers
AnsweredChanged depreciation method externally reviewed. Q2 depreciation ₹8 Cr for Cavite Biofuel. Expect ₹8 Cr/quarter Q3-Q4. Cumulative ~₹175 Cr for H1 impact from method change.
Hitachi JV margin pressure — Manish Goyal, Thingwise Wealth Managers
DodgedStrong order book, margins expected higher maybe 5-7% vs last year. Booked large export orders, export base growing. Expect turnover ~7-8% higher vs prior year.
Products division order composition — Digant Haria, Greenedge Wealth
AnsweredOrders from auto, oil & gas, petrochem, cement, steel. Wide industry spread. Expansions on schedule. ₹1,200 Cr annual revenue potential from ₹502 Cr capex. Some revenue coming this year, bulk next 2-3 years.
Saraswati Sugar Mills cane supply — Sandeep Baid, Individual
PartialLocated Haryana. Supply not enough this season. Expect marginally more cane than last year. Real production starts December. Q4 utilization ~90%. Commodity prices firm, should improve realization.
Philippines ethanol unit path to breakeven — Rabindra Nath Nayak, Nirmal Bang
DodgedPlant under maintenance Q3. Feedstock available December when sugarcane season starts. Q3 70-75% utilization, Q4 90% expected. No quarterly loss guidance; depreciation ₹8 Cr, interest clear, forex unclear.
Capex increase potential — Bajrang Bafna, Sunidhi Securities
Partial₹500 Cr program will yield ₹1,200 Cr incremental revenue. Evaluating if we might top it up, not finalized. FY29 target if all on schedule. Only small revenue <₹100 Cr this year; bulk next 2 years.
Order book fixity & price variation — Digant Haria, Greenedge Wealth
AnsweredMost orders fixed-price. Limited price variation. Manage via back-to-back quotes, rate contracts, contingencies. Risk mitigation via short-cycle orders to reduce customer liquidity risk.
Guidance
FY27 standalone revenue growth 15-17% (raised)
MediumPrior guidance 10-12%. Upgrade driven by ₹4,844 Cr order booking visibility. But consolidated delivered 9.4%, indicating 5-7% subsidiary drag. Second half must deliver 3,200-3,300 Cr to hit target. Execution risk: Philippines ramp, Saraswati supply.
Manufacturing EBIT 12-13% (maintained, already beat to 13.7%)
HighQ2 achieved 13.7%, indicating pricing power. Expected to stay 12-13% range for full year despite commodity inflation headwinds. Input cost inflation partially offset by short-cycle order mix.
Projects EBIT margin to improve to ~6% by year-end (from 5.7%)
MediumCurrently 5.7% vs 6% target. Management expects margin expansion as capex benefits materialize and technology pivot to shorter-cycle orders accelerates. Execution dependent on order execution pace.
₹502 Cr capex expansion for ₹1,200 Cr annual revenue potential by FY29
MediumAll new facilities (Bhartoli, SEZ Dabhei, Ratangarh, Hawa) running on schedule, progressively completing through Q4 FY27. Management evaluating potential increase from ₹500 Cr baseline. Revenue contribution <₹100 Cr FY27, bulk in FY28-29.
Risks the call surfaced
Philippines biofuel losses
HighCavite Biofuel ethanol plant incurred ₹164 Cr cumulative loss H1 (depreciation ₹50+, interest, forex loss). Operating at 65-70% capacity on molasses feedstock. Real sugarcane-based production starts December. Path to profitability unclear; management evasive on quarterly loss guidance.
Saraswati Sugar Mills cane supply
MediumH1 PBIT loss ₹60 Cr due to lower cane availability (67 Cr units vs 70+ normal) in Haryana captive area. Lower production & realizations drove margin compression. Supply dependent on weather & farmer planting patterns.
Consolidated vs standalone divergence
MediumStandalone revenue grew 17% YoY but delivered consolidated result shows only 9.4% growth. ~750 bps gap driven by Philippines & Saraswati drag. If standalone growth guidance (15-17%) is maintained while subsidiaries remain weak, consolidated may miss 10-12% prior guidance again.
Geopolitical & commodity inflation
MediumMaterial cost inflation (steel, copper, aluminum) skewed up 10% YoY due to Middle East tensions. Shipping delays, higher freight surcharges. Management notes most increased costs absorbed via contingency provisions, but longer-term margin risk if inflation persists.
Capex materialization timeline
Medium₹502 Cr capex targeting ₹1,200 Cr annual revenue by FY29. Only <₹100 Cr revenue expected FY27, bulk in FY28-29. Execution delays would push realization further. Management evaluating increase from ₹500 Cr but no decision finalized.
Management
Score 7/10. Clear on order pipeline & capex. Transparent on manufacturing margin beat. Evasive on Philippines ethanol ramp timeline & quarterly loss path. Limited disclosure on product-wise revenue/margin breakdown. NDA-shields product division strategy; candid on capex spend & timeline. Beat manufacturing margin guidance (13.7% vs 12-13%). Order book at all-time high ₹8,757 Cr indicates strong execution. Missed consolidated revenue growth (9.4% vs prior 10-12% target). Subsidiary performance drag not fully explained. Capex facilities on schedule but realization timing uncertain (FY28-29 vs FY29).
1 · Q3 FY27 (Dec 2026)
Cavite biofuel depreciation stabilizes; Philippines ethanol real production begins post-sugarcane start
2 · Q4 FY27 (Mar 2027)
Saraswati Sugar Mills capacity utilization improves; new manufacturing capacity from Bhartoli, SEZ, Dabhei commences
3 · FY28-29
₹502 Cr capex materialization: ₹1,200 Cr incremental revenue target from new press, skids, modules facilities
Margin expansion in core manufacturing (13.7% vs 12-13% guided) offset by near-term execution risk.
ISGEC Q2: PAT ₹66 Cr, revenue growth on guidance track; Philippines unit stays loss-making
PAT +17.61% YoY · revenue +9.42% · margins expanding
₹1,850.39 Cr
+9.42% YoY
₹66.19 Cr
+17.61% YoY
3.56%
+0.3pp YoY
₹7.67
Isgec Heavy Engineering's consolidated PAT came in at ₹66.19 Cr for Q2 FY27, up 17.6% YoY against the ₹56.28 Cr previously reported a year ago, and a sharp 278% rebound from a weak ₹17.50 Cr in Q1 FY27. Consolidated revenue grew 9.4% YoY to ₹1,850.39 Cr but fell 6.5% QoQ from ₹1,980.00 Cr — projects-heavy revenue recognition is lumpy quarter to quarter. No analyst consensus could be verified for this print; ISGEC has thin formal brokerage coverage, so the result cannot be benchmarked against a credible Street number.
Q2 FY-2027 vs prior quarters
The cleaner read is on the standalone (parent) business, which management's own FY27 guidance targets: 10-12% revenue growth with manufacturing EBIT margins of 12-13% and projects margins of 5-6%. Standalone revenue grew 17.2% YoY this quarter (₹1,456.58 Cr vs ₹1,243.13 Cr) and 35.2% for H1 FY27 (₹3,009.62 Cr vs ₹2,226.93 Cr) — comfortably ahead of the guided band. Segment margins landed right on target: Manufacturing EBIT margin was 13.7% (7,355/53,713 lakh) against the 12-13% guided range, and Industrial Projects margin was 5.7% (5,807/101,475 lakh) within the 5-6% band. Consolidated margins also improved sequentially — OPM (ex-other income) rose to 7.97% from 6.24% in Q1, and NPM to 3.58% from 0.88%.
The stock went into the print at ₹958, up 6.5% over the past month of trading.
FY27 standalone revenue growth 10-12% with manufacturing EBIT margins 12-13% and projects margins 5-6%. Capex ₹502 Cr for manufacturing capacity expansion targeting ₹1,200 Cr annual revenue potential by 2028-29, with phased completions through Q1 FY28.
— This quarter: beat
The gap between the two numbers — standalone PAT of ₹118.14 Cr nearly double the consolidated ₹66.19 Cr — is explained by loss-making subsidiaries, chiefly the Philippines ethanol plant (Cavite Biofuel Producers), which posted a ₹60.16 Cr segment loss this quarter, narrower than the ₹75.71 Cr loss a year earlier but still the single biggest drag on group earnings. The company also issued ₹61 Cr of comfort letters for a JV/subsidiary this quarter, consistent with continued financial support to group entities including this loss-making asset. No management press release or commentary was available in this filing to corroborate or contest these figures with the company's own framing; the prior concall's cautious tone on near-term execution is broadly consistent with the sequential dip in projects-segment revenue this quarter even as the manufacturing segment and margins tracked guidance.
W1
Whether the Philippines ethanol plant's segment loss (-₹60.16 Cr this quarter, from -₹75.71 Cr a year ago) keeps narrowing toward breakeven
W2
Whether H2 FY27 standalone revenue growth moderates toward the guided 10-12% band after a ~35% H1 run-rate
W3
Manufacturing segment margin holding within/above the guided 12-13% band (13.7% this quarter) as the ₹502 Cr capacity-expansion capex progresses
Converted from ₹ Lakh to ₹ Cr; no exceptional items this quarter for either basis. Consolidated PAT ₹66.19 Cr is total profit for the period (owners' share ₹56.41 Cr + NCI ₹9.78 Cr), matching our records' netProfit convention. The filing's own restated Q2 FY26 comparative (PAT ₹12.55 Cr, EPS ₹0.03) is far lower than the ₹56.28 Cr previously-reported figure used here for YoY, after Isgec reclassified the Philippines ethanol subsidiary from discontinued to continuing operations (Note 7) — so true like-for-like PAT growth is much steeper than the +17.6% shown, driven mainly by a narrower Philippines segment loss, not core-business strength.